Evidence map›Paper›PMID 39238451›Full record

ArticleJournal of integrative bioinformatics2024

MCMVDRP: a multi-channel multi-view deep learning framework for cancer drug response prediction.

Xiangyu Li, Xiumin Shi, Yuxuan Li, Lu Wang

Abstract read
In one paragraph

Article in Journal of integrative bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiangyu LiSchool of Information and Electronics, 47833 Beijing Institute of Technology , Beijing, China.
Xiumin ShiSchool of Information and Electronics, 47833 Beijing Institute of Technology , Beijing, China.ORCID https://orcid.org/0000-0002-7749-5940
Yuxuan LiSchool of Information and Electronics, 47833 Beijing Institute of Technology , Beijing, China.
Lu WangDepartment of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.ORCID https://orcid.org/0000-0001-7505-7894

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug therapy remains the primary approach to treating tumours. Variability among cancer patients, including variations in genomic profiles, often results in divergent therapeutic responses to analogous anti-cancer drug treatments within the same cohort of cancer patients. Hence, predicting the drug response by analysing the genomic profile characteristics of individual patients holds significant research importance. With the notable progress in machine learning and deep learning, many effective methods have emerged for predicting drug responses utilizing features from both drugs and cell lines. However, these methods are inadequate in capturing a sufficient number of features inherent to drugs. Consequently, we propose a representational approach for drugs that incorporates three distinct types of features: the molecular graph, the SMILE strings, and the molecular fingerprints. In this study, a novel deep learning model, named MCMVDRP, is introduced for the prediction of cancer drug responses. In our proposed model, an amalgamation of these extracted features is performed, followed by the utilization of fully connected layers to predict the drug response based on the IC50 values. Experimental results demonstrate that the presented model outperforms current state-of-the-art models in performance.

Indexed as

Antineoplastic AgentsDeep LearningNeoplasmsHumansAntineoplastic Agentsbidirectional long short-term memoryconvolutional neural networkdeep learningdrug response predictiongraph convolutional network

Identifiers

PMID39238451
PMCPMC11602226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.